Year

Category

2022-09-27

Kancera reports good progress of recruitment in ongoing phase IIa study of KAND567 in myocardial infarction and the decision to allow for recruitment of additional patients

Kancera AB (publ) is today reporting that patient recruitment to the ongoing phase IIa study of KAND567 in myocardial infarction patients is progressing well and 54 patients of the targeted 60 patients have been enrolled so far. The company...

Read More
2022-09-22

Kancera reports convincing preclinical results and decision to initiate clinical development of KAND567 in ovarian cancer

Kancera AB (publ) is today reporting new results that confirm that the company’s Fractalkine-blocking candidate drug may increase the efficacy of platinum-based chemotherapy and reduce tumor growth in animal models of ovarian cancer. As a result, Kancera has met...

Read More
2022-08-22

Interim report second quarter, January 1 – June 30, 2022, Kancera ab (publ.), org.nr. 556806-8851

This is a translation of the interim report published in swedish on Januaryt 19th

Read More
2022-07-29

Correction: Interim report first quarter 2022, 1 January – 31 March 2022 Kancera AB (publ.), org.nr. 556806-8851

Due to technical reasons this report was only published as a press release, but did not show up in the Finacial reports section on the Kancera web page. This is now corrected. First quarter in brief January – MarchFinancial...

Read More
2022-05-25

Kancera receives patent grant in US for the drug candidate KAND145

Kancera AB announces today that the US Patent Office (USPTO) has issued a patent that protects the chemical structure of Kancera's fractalkine blocker KAND145. This patent, US 11,339,183, is owned by Kancera and is valid through 2039.

Read More